Jpmorgan Chase & CO In8 Bio, Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in In8 Bio, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 85 shares of INAB stock, worth $19. This represents 0.0% of its overall portfolio holdings.
Number of Shares
85
Previous 78
8.97%
Holding current value
$19
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding INAB
# of Institutions
27Shares Held
7.62MCall Options Held
0Put Options Held
0-
Aigh Capital Management LLC Baltimore, MD1.67MShares$385,1660.18% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.42MShares$327,4960.0% of portfolio
-
683 Capital Management, LLC New York, NY1.35MShares$310,5690.03% of portfolio
-
Sigma Planning Corp Ann Arbor, MI851KShares$195,7940.01% of portfolio
-
Ensign Peak Advisors, Inc Salt Lake City, UT829KShares$190,7100.0% of portfolio
About IN8BIO, INC.
- Ticker INAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,502,200
- Market Cap $5.64M
- Description
- IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of...